2022
DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation
Jawad M, Afkhami M, Ding Y, Zhang X, Li P, Young K, Xu ML, Cui W, Zhao Y, Halene S, Al-Kali A, Viswanatha D, Chen D, He R, Zheng G. DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation. Frontiers In Oncology 2022, 12: 849376. PMID: 35296003, PMCID: PMC8918526, DOI: 10.3389/fonc.2022.849376.Peer-Reviewed Original ResearchWorse progression-free survivalProgression-free survivalMyelodysplastic syndromeAML transformationMyeloid neoplasmsMDS casesHigh riskR882 mutationsClonal hematopoiesisIndependent risk factorUnique clinicopathologic featuresTertiary medical institutionsDifferent treatment approachesUnique clinicopathologicExcess blastsSevere leukopeniaClinicopathologic featuresMutant patientsRisk factorsLarge cohortTherapeutic implicationsTreatment approachesClinical implicationsClinical-genomic databaseNeoplasms
2009
Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes
Wang R, Gross CP, Halene S, Ma X. Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leukemia Research 2009, 33: 1594-1598. PMID: 19324411, PMCID: PMC2749891, DOI: 10.1016/j.leukres.2009.02.005.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeHazard ratioComorbid conditionsMDS patientsCharlson indexMultivariate Cox proportional hazards modelPrognosis of MDSChronic obstructive pulmonary diseaseCox proportional hazards modelLarge population-based studyCongestive heart failureObstructive pulmonary diseaseRole of comorbiditiesMedian survival timePopulation-based studyProportional hazards modelMDS survivalHeart failurePulmonary diseaseIndependent determinantsShorter survivalLarge cohortSurvival timeHazards modelComorbidities